Improved Outcomes For Patients Treated With Lantus(R) And Apidra(R) Regimen Compared With Sliding Scale Insulin

Sanofi-aventis (EURONEXT: SAN) (NYSE: SNY) announced that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus® (insulin glargine [rDNA origin] injection) once-daily and Apidra® (insul…